2016
Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis
Chastre A, Hafler DA, O'Connor KC. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. New England Journal Of Medicine 2016, 374: 1495-1496. PMID: 27074083, PMCID: PMC4918464, DOI: 10.1056/nejmc1513302.Peer-Reviewed Original Research
2007
Protective and therapeutic role for αB-crystallin in autoimmune demyelination
Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O’Conner K, Hafler DA, Sobel RA, Robinson WH, Steinman L. Protective and therapeutic role for αB-crystallin in autoimmune demyelination. Nature 2007, 448: 474-479. PMID: 17568699, DOI: 10.1038/nature05935.Peer-Reviewed Original Research
1992
Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis
Hafler D, Brod S, Weiner H. Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis. Clinical Medicine And The Nervous System 1992, 301-307. DOI: 10.1007/978-1-4471-3184-7_15.Peer-Reviewed Original ResearchMultiple sclerosisT cellsAutoimmune diseasesNervous systemAutoreactive T cellsPatient T cellsCentral nervous systemInitial inductionMyelin basic proteinSpecific immunotherapyImmune targetsWhite matter structuresImmune regulationProteolipid proteinSclerosisMatter structuresDiseaseBasic proteinDestructive processesImmunotherapyDemyelinationInflammationCareful regulation